Highest-materiality recent filing
Indivior eliminates Chief Scientific Officer role; Heidbreder to depart Dec 31, 2026
CSO position eliminated effective June 1, 2026; Dr. Christian Heidbreder transitions to advisory role through year-end.
Indivior launches $175M accelerated share repurchase with Barclays
Initial prepayment of $175M; received 3,717,473 shares from Barclays.
Indivior Q1 net revenue $317M (+19% YoY); raises FY2026 guidance
Q1 GAAP net income $89M ($0.69 EPS); non-GAAP net income $123M ($0.96 EPS).
Indivior issues $500M 0.625% convertible notes due 2031; repays existing debt
$500M principal of 0.625% Convertible Senior Notes due March 15, 2031 issued; initial purchasers' option fully exercised for additional $50M.
Indivior prices upsized $450M convertible notes at 0.625% due 2031
Principal amount $450M (upsized from $400M); 0.625% interest, matures March 15, 2031.
$400M aggregate principal amount of convertible senior notes due 2031, with initial purchasers' option for additional $60M.
Indivior Q4 earnings beat; SUBLOCADE rev $252M (+30%); new $400M buyback; FY26 guidance reaffirmed
Q4 total net revenue $358M (+20% YoY); SUBLOCADE net revenue $252M (+30%); GAAP diluted EPS $0.79 vs $0.17
Indivior completes U.S. Domestication; begins trading on Nasdaq as Delaware corp under INDV
Scheme of Arrangement effective Jan 23, 2026; Indivior U.S. becomes ultimate parent of Indivior U.K.
Indivior provides FY2026 guidance: revenue $1.125B-$1.195B, Adj. EBITDA $535M-$575M
Total net revenue expected $1,125M-$1,195M; SUBLOCADE net revenue $905M-$945M.
Indivior added to S&P SmallCap 600 index effective December 22, 2025
Inclusion in S&P SmallCap 600 index effective today, December 22, 2025.
Indivior CEO and CFO receive base salary increases effective Jan 1, 2026
CEO Joseph Ciaffoni salary increased from $1,050,000 to $1,115,000.
Indivior shareholders approve scheme of arrangement to restructure, court hearing Jan 22, 2026
Amended articles effective Dec 11 to facilitate scheme ensuring all shareholders become holders of Indivior Pharmaceuticals shares.
Indivior pays $295M to DOJ, concludes legacy resolution agreement
Paid $295M in full to DOJ using cash on hand, resolving 2020 Resolution Agreement.
Indivior proposes re-domestication from UK to Delaware; shareholder vote set for Dec 11, 2025
Scheme circular filed: EGM on Dec 11, 2025 to vote on re-domestication via scheme of arrangement.
Indivior estimates $105-130M restructuring charges; exits six non-US markets
Total pre-tax restructuring charges estimated at $105-130M, with $65M recognized in Q3 2025.
Indivior Q3 net revenue $314M (+2% YoY); raises FY2025 guidance materially
SUBLOCADE net revenue $219M (+15% YoY); U.S. SUBLOCADE up 14% to $203M.
Indivior proposes redomiciliation to Delaware via new US parent IPI
Each Indivior PLC share exchanged for one share of new Delaware corporation Indivior Pharmaceuticals, Inc. (IPI).
Indivior announces restructuring charges of $39-$50 million as part of Indivior Action Agenda
Headcount reductions expected to incur pre-tax severance charges of approximately $16 to $19 million in Q3 2025.
New employment agreement for CFO Ryan Preblick, effective Jan 1, 2025, aligns with current U.S. executive forms.
Indivior assigns new director Kingsley to Audit & Risk and Compensation committees
Stuart A. (Tony) Kingsley appointed non-executive director effective July 1, 2025.
Indivior raises FY 2025 guidance after Q2 beat; SUBLOCADE revenue up 9%
Q2 total net revenue $302M (+1% YoY); net income $18M ($0.14 EPS); non-GAAP diluted EPS $0.51.
Indivior added to Russell 2000 and 3000 indexes effective June 30, 2025
Inclusion follows 2025 Russell indexes annual reconstitution; membership lasts one year.
Indivior appoints Tony Kingsley to board; directors adopt equity purchase plan
Appointed Tony Kingsley as independent non-executive director effective July 1, 2025.
Indivior posts updated corporate presentation June 2025; content not fully disclosed
Company added 'Corporate Presentation June 2025' to its investor relations website on June 2, 2025.
Indivior to cancel London Stock Exchange secondary listing, maintain Nasdaq primary listing
London delisting effective July 25, 2025; last trading on LSE July 24, 2025.
Indivior corrects AGM vote tally for Dr. Wheadon election: against votes now 14.6M
Corrected votes against Dr. David Wheadon's election from 4,624,894 to 14,624,894.
Joe Ciaffoni commenced as CEO on May 8, 2025, following shareholder approval of remuneration policy.
Indivior Q1 net revenue $266M, in line; GAAP EPS $0.38, non-GAAP $0.41; FY guidance unchanged
Net revenue $266M (-6% YoY), in line with expectations; U.S. net revenue $222M (-8%).
Indivisor names Joe Ciaffoni CEO; proposes incentive plan with share price targets up to $35
Joe Ciaffoni to become CEO effective upon shareholder approval of new Directors' Remuneration Policy at May 8, 2025 AGM.
Indivior appoints Joe Ciaffoni as CEO, reduces board to 7, enters amended Oaktree deal
Joe Ciaffoni appointed CEO effective after 2025 AGM but no later than Aug 1, 2025; Mark Crossley remains CEO until then.
Effective June 1, 2026, Indivior Pharmaceuticals, Inc. (the "Company" or the "Registrant") will eliminate the position of Chief Scientific Officer.
Also, pursuant to his separation agreement, Mark Crossley stepped down as CEO of the Company and as a director.
Following shareholder approval of the Company’s Directors’ Remuneration Policy, the Company and Joe Ciaffoni agreed that his employment as CEO would commence on May 8, 2025.
Peter Bains and Jo LeCouilliard have decided not to stand for re-election at the Company’s Annual General Meeting.
the announcement on February 27, 2025 of the appointment of Joe Ciaffoni as Chief Executive Officer of the Company
Peter Bains and Jo LeCouilliard have decided not to stand for re-election at the Company’s Annual General Meeting.
Robert Schriesheim notified the Board of his resignation therefrom on March 2, 2025 with immediate effect.
Max materiality 0.85 · Median 0.65 · Most common event other_material